3.6
ValidityScore
Valid or Invalid?
-
2010RCT
-
Acuña-Castroviejo D, Chahbouni M, Escames G, García JA, López LC, Molina-Carballo A, Muñoz-Hoyos A, Sevilla B, Venegas C
-
«Abstract: Duchenne muscular dystrophy (DMD), a lethal disorder characterized by dystrophin absence, courses with chronic inflammation, sarcolemmal damage, and skeletal muscle degeneration. Among the multiple pathogenic mechanisms proposed for DMD, oxidative stress and inflammation are directly involved in the dystrophic process. Unfortunately, there is no current treatment for DMD, and the inflammatory process is an important target for therapies. Based on the antioxidant and anti-inflammatory properties of melatonin, we investigated whether melatonin treatment may reduce the dystrophic process. Ten DMD patients age 12.8 +/- 0.98 yr, were treated with melatonin (60 mg at 21:00 hr plus 10 mg at 09:00 hr), and plasma levels of lipid peroxidation (LPO), nitrites (NO(x)), interleukin (IL)-1beta, IL-2, IL-6, tumor necrosis factor-alpha, IFN-γ, and plasma markers of muscle injury, were determined at 3, 6 and 9 months of treatment. Healthy age- and sex-matched subjects were used as controls. The results show a significant increase in LPO, NO(x), and cytokine levels in plasma of DMD patients compared with controls. Melatonin administration reduced these values to control levels at 3 months of treatment, decreasing further 9 months later. In parallel, melatonin also reduced plasma levels of creatine kinase (CK; 50%), lactate dehydrogenase (28%), aspartate aminotransferase (28%), alanine aminotransferase (20%), and myoglobin (13%). These findings strongly support the conclusion that melatonin administration significantly reduced the hyperoxidative and inflammatory process in DMD patients, reducing the muscle degenerative process.»
- Dose: en DMD patients age 12.8 +/- 0.98 yr, were treated with melatonin (60 mg at 21:00 hr plus 10 mg at 09:00 hr)
- Organism: Humans
- Strong Magnitude of Effect.
-
#Adolescent, Analysis of Variance, Case-Control Studies, Child, Cytokines / blood*, Darío Acuña-Castroviejo, Duchenne / blood, Duchenne / drug therapy*, Female, Germaine Escames, Humans, Lipid Peroxidation, MEDLINE, Male, Mariam Chahbouni, Melatonin / blood, Melatonin / therapeutic use*, Muscular Dystrophy, NCBI, NIH, NLM, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, Nitrates / blood, Nitrites / blood, Non-U.S. Gov', Oxidative Stress / drug effects*, PubMed Abstract, Research Support, doi:10.1111/j.1600-079X.2010.00752.x, pmid:20210854more...
-
added it
6 months ago
on Oct 22, 2021
ranked